Medicenna Therapeutics Corp. (TSX:MDNA)
Canada · Delayed Price · Currency is CAD 0.8700
-0.0100 (-1.14%)
At close: Mar 3, 2026
Medicenna Therapeutics Employees
Medicenna Therapeutics had 18 employees as of March 31, 2025. The number of employees increased by 2 or 12.50% compared to the previous year.
Employees
18
Change (1Y)
2
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-721.56K CAD
Market Cap
72.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 18 | 2 | 12.50% |
| Mar 31, 2024 | 16 | 0 | - |
| Mar 31, 2023 | 16 | -2 | -11.11% |
| Mar 31, 2022 | 18 | 5 | 38.46% |
| Mar 31, 2021 | 13 | 6 | 85.71% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Medicenna Therapeutics News
- 13 days ago - Medicenna Therapeutics Announces Participation in Upcoming Conferences - GlobeNewsWire
- 15 days ago - Medicenna To Present Updated Bizaxofusp Data At 7th Annual Glioblastoma Development Summit - Nasdaq
- 18 days ago - Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 19 days ago - Medicenna Announces Changes to Board Composition - GlobeNewsWire
- 6 weeks ago - Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook - GlobeNewsWire
- 2 months ago - Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy Transcript - Seeking Alpha
- 2 months ago - Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy - Slideshow - Seeking Alpha
- 2 months ago - Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors - GlobeNewsWire